Selumetinib plus azacitidine for high-risk blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests whether selumetinib and azacitidine can help people with high-risk chronic blood cancers. You may qualify if your disease is higher risk and has either come back, not responded, or needs treatment because of low blood counts or other concerning features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have a confirmed diagnosis of one of these: high-risk MDS, MDS/MPN (including CMML or atypical CML), or high-risk myelofibrosis
- Have disease that is relapsed or refractory, or needs treatment because of low blood counts, excess blasts, or an enlarged spleen
- Have not taken a MEK inhibitor before (this trial looks for no prior MEK-inhibitor treatment)
- Be well enough for treatment (ECOG 0–2) and have adequate kidney and liver function
- Be able to use birth control if applicable and sign informed consent (and not be pregnant or breastfeeding)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like MDS, AML, or CMML, especially those who have leftover leukemia cells before a stem cell transplant. The goal is to see if this treatment can improve outcomes.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.